These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38583254)

  • 21. Design and synthesis of novel pyrazolo[3,4-d]pyrimidin-4-one bearing quinoline scaffold as potent dual PDE5 inhibitors and apoptotic inducers for cancer therapy.
    Ibrahim TS; Hawwas MM; Taher ES; Alhakamy NA; Alfaleh MA; Elagawany M; Elgendy B; Zayed GM; Mohamed MFA; Abdel-Samii ZK; Elshaier YAMM
    Bioorg Chem; 2020 Dec; 105():104352. PubMed ID: 33080494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 3D-QSAR, Virtual Screening, Docking and Design of Dual PI3K/mTOR Inhibitors with Enhanced Antiproliferative Activity.
    Oluić J; Nikolic K; Vucicevic J; Gagic Z; Filipic S; Agbaba D
    Comb Chem High Throughput Screen; 2017 Aug; 20(4):292-303. PubMed ID: 28460621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 3-Arylamino-quinoxaline-2-carboxamides inhibit the PI3K/Akt/mTOR signaling pathways to activate P53 and induce apoptosis.
    Chen NY; Lu K; Yuan JM; Li XJ; Gu ZY; Pan CX; Mo DL; Su GF
    Bioorg Chem; 2021 Sep; 114():105101. PubMed ID: 34175723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis and antitumor activity of novel thiophene- triazine derivatives bearing arylurea unit as potent PI3K/mTOR inhibitorss.
    Xu S; Luo L; Sun X; Yang Y; Guo Q; Jiang Z; Wu Y
    Bioorg Med Chem; 2023 Jan; 78():117133. PubMed ID: 36599263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
    Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
    Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.
    Kashiyama T; Oda K; Ikeda Y; Shiose Y; Hirota Y; Inaba K; Makii C; Kurikawa R; Miyasaka A; Koso T; Fukuda T; Tanikawa M; Shoji K; Sone K; Arimoto T; Wada-Hiraike O; Kawana K; Nakagawa S; Matsuda K; McCormick F; Aburatani H; Yano T; Osuga Y; Fujii T
    PLoS One; 2014; 9(2):e87220. PubMed ID: 24504419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis and anticancer evaluation of new 4-anilinoquinoline-3-carbonitrile derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
    Zou M; Li J; Jin B; Wang M; Chen H; Zhang Z; Zhang C; Zhao Z; Zheng L
    Bioorg Chem; 2021 Sep; 114():105200. PubMed ID: 34375195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis and pharmacological evaluation of 2-arylurea-1,3,5-triazine derivative (XIN-9): A novel potent dual PI3K/mTOR inhibitor for cancer therapy.
    Sun X; Zhang B; Luo L; Yang Y; He B; Zhang Q; Wang L; Xu S; Zheng P; Zhu W
    Bioorg Chem; 2022 Dec; 129():106157. PubMed ID: 36209563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design and Synthesis of Coumarin Derivatives as Novel PI3K Inhibitors.
    Ma CC; Liu ZP
    Anticancer Agents Med Chem; 2017; 17(3):395-403. PubMed ID: 26902599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery and synthesis of 2-amino-1-methyl-1H-imidazol-4(5H)-ones as GPCR ligands; an approach to develop breast cancer drugs via GPCR associated PAR1 and PI3Kinase inhibition mechanism.
    Ashok SR; Shivananda MK; Manikandan A; Chandrasekaran R
    Bioorg Chem; 2019 May; 86():641-651. PubMed ID: 30822721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis and biological activity of novel 2,3,4,5-tetra-substituted thiophene derivatives as PI3Kα inhibitors with potent antitumor activity.
    Liao W; Wang Z; Han Y; Qi Y; Liu J; Xie J; Tian Y; Lei Q; Chen R; Sun M; Tang L; Gong G; Zhao Y
    Eur J Med Chem; 2020 Jul; 197():112309. PubMed ID: 32375077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, crystal structures and anticancer activity of 4-substituted quinolines to target PDK1.
    Vennila KN; Sunny D; Madhuri S; Ciattini S; Chelazzi L; Elango KP
    Bioorg Chem; 2018 Dec; 81():184-190. PubMed ID: 30138906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis and biological evaluation of substituted 2-(thiophen-2-yl)-1,3,5-triazine derivatives as potential dual PI3Kα/mTOR inhibitors.
    Zhang B; Zhang Q; Xiao Z; Sun X; Yang Z; Gu Q; Liu Z; Xie T; Jin Q; Zheng P; Xu S; Zhu W
    Bioorg Chem; 2020 Jan; 95():103525. PubMed ID: 31887474
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M).
    Shaheen MA; El-Emam AA; El-Gohary NS
    Bioorg Chem; 2020 Dec; 105():104274. PubMed ID: 33339080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, in-vitro antiproliferative activity and kinase profile of new picolinamide based 2-amido and ureido quinoline derivatives.
    El-Damasy AK; Seo SH; Cho NC; Kang SB; Pae AN; Kim KS; Keum G
    Eur J Med Chem; 2015 Aug; 101():754-68. PubMed ID: 26218653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design and synthesis of benzofuro[3,2-b]pyridin-2(1H)-one derivatives as anti-leukemia agents by inhibiting Btk and PI3Kδ.
    Liu L; Shi B; Li X; Wang X; Lu X; Cai X; Huang A; Luo G; You Q; Xiang H
    Bioorg Med Chem; 2018 Aug; 26(15):4537-4543. PubMed ID: 30077608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis, and biological evaluation of novel 6-(pyridin-3-yl) quinazolin-4(3H)-one derivatives as potential anticancer agents via PI3K inhibition.
    Yang H; Li Q; Su M; Luo F; Liu Y; Wang D; Fan Y
    Bioorg Med Chem; 2021 Sep; 46():116346. PubMed ID: 34403956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, Synthesis, and Biological Evaluation of Imidazo[1,2-
    Yu Y; Han Y; Zhang F; Gao Z; Zhu T; Dong S; Ma M
    J Med Chem; 2020 Mar; 63(6):3028-3046. PubMed ID: 32069401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, Synthesis, Formulation, and Bioevaluation of Trisubstituted Triazines as Highly Selective mTOR Inhibitors for the Treatment of Human Breast Cancer.
    Sun Q; Chu Y; Zhang N; Chen R; Wang L; Wu J; Dong Y; Li H; Wang L; Tang L; Zhan C; Zhang JQ
    J Med Chem; 2024 May; 67(9):7330-7358. PubMed ID: 38661655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. (
    Rageot D; Bohnacker T; Keles E; McPhail JA; Hoffmann RM; Melone A; Borsari C; Sriramaratnam R; Sele AM; Beaufils F; Hebeisen P; Fabbro D; Hillmann P; Burke JE; Wymann MP
    J Med Chem; 2019 Jul; 62(13):6241-6261. PubMed ID: 31244112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.